FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL
OMB Number:3235-0104
Expires:02/28/2011
Estimated average burden
hours per response0.5

1. Name and Address of Reporting Person *

Schmid Timothy

2. Date of Event Requiring Statement (Month/Day/Year)

10/23/2023

3. Issuer Name and Ticker or Trading Symbol

JOHNSON & JOHNSON [JNJ]
(Last)
(First)
(Middle)


ONE JOHNSON & JOHNSON PLAZA

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
EVP, WW Chair, MedTech

5. If Amendment, Date Original Filed (Month/Day/Year)

(Street)

NEW BRUNSWICK, NJ 08933
(City)
(State)
(Zip)

6. Individual or Joint/Group Filing

(Check applicable line)

__X__ Form Filed by One Reporting Person
_____ Form Filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned (Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Common Stock

8,979
D
 


Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and Expiration Date (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Employee Stock Options (Right to Buy)

02/09/201902/08/2026

Common Stock

15,571 $101.87D 

Employee Stock Options (Right to Buy)

02/13/202002/13/2027

Common Stock

13,625 $115.67D 

Employee Stock Options (Right to Buy)

02/12/202102/11/2028

Common Stock

8,998 $129.51D 

Employee Stock Options (Right to Buy)

02/11/202202/11/2029

Common Stock

11,070 $131.94D 

Employee Stock Options (Right to Buy)

02/10/202302/10/2030

Common Stock

22,527 $151.41D 

Employee Stock Options (Right to Buy)

  (1) 02/13/2033

Common Stock

12,388 $162.75D 

Employee Stock Options (Right to Buy)

02/08/202402/08/2031

Common Stock

21,574 $164.62D 

Employee Stock Options (Right to Buy)

02/14/202502/14/2032

Common Stock

17,431 $165.89D 

Restricted Share Units

  (2)   (2)

Common Stock

1,497 (2) D 

Restricted Share Units

02/08/202402/08/2024

Common Stock

1,964 (3) D 

Restricted Share Units

02/14/202502/14/2025

Common Stock

1,765 (3) D 



Explanation of Responses:
1.

The Stock Option Award was granted on February 13, 2023 and vests in three equal annual installments beginning on the first anniversary of the grant date.

2.

The Restricted Share Units were granted on February 13, 2023 and vest in three annual equal installments beginning on the first anniversary of the grant date.

3.

Each Restricted Share Unit represents a contingent right to acquire one share of Company Common Stock.

Remarks:

schmidpoa1.txt



Signatures

Raavi Deol, as attorney-in-fact, for Timothy Schmid

11/02/2023
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY
Executive Officers

Know all persons by these presents, that the undersigned hereby
constitutes and appoints each of Marc Larkins, Robert McKeehan,
Laura McFalls, Duane van Arsdale and Raavi Deol, signing singly, as the
undersigned's true and lawful attorneys-in-fact to:

(1)	complete and execute for and on behalf of the undersigned, in the
undersigned's capacity as an executive officer of Johnson & Johnson
(the "Company"), Forms 3, 4 and 5 (including any amendments thereto)
in accordance with Section 16(a) of the Securities Exchange Act of 1934,
as amended, and the rules and regulations promulgated thereunder
(the "Exchange Act") and Form 144 in accordance with Rule 144 of the
Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder (the "Securities Act");
(2)	prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the United States Securities and Exchange Commission (the "SEC")
an Application for EDGAR Access (Form ID), including amendments thereto, and
any other documents necessary or appropriate to obtain codes and passwords
enabling the undersigned to make electronic filings with the SEC of reports
required by Section 16(a) of the Exchange Act, or any rule or regulation of
the SEC;
(3)	do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4, 5
and 144 (including any amendments thereto) and timely file such form with the
SEC and any stock exchange or similar authority; and
(4)	take any other action of any type whatsoever in connection with the
  foregoing which, in the opinion of such attorney-in-fact, may be of benefit
to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf
of the undersigned pursuant to this Power of Attorney shall be in such form
and shall contain such terms and conditions as such attorney-in-fact may
 approve in such attorney-in-fact's discretion.
	The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might
or could do if personally present, with full power of substitution or
revocation, hereby ratifying and confirming all that such attorney-in-fact,
or such attorney-in-fact's substitute or substitutes, shall lawfully do or
cause to be done by virtue of this power of attorney and the rights and powers
herein granted.  The undersigned acknowledges that the foregoing
attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, (i) any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act or
Rule 144 of the Securities Act or (ii) any liability of the undersigned for
failure to comply with such requirements. The undersigned agrees that each such
attorney-in-fact may rely entirely on information furnished orally or in
writing by or at the direction of the undersigned to the attorney-in-fact.
		This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, 5 and 144 with respect
to the undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of the date set forth below.

	/s/ Timothy Schmid
	Name:  Timothy Schmid
	Date:    October 23, 2023